Biomarkers of Glioma

Liang, Shufang; Shen, Guobo

doi:10.5772/24159

Cited by 8 publications

(7 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The aim of this study is to identify promising prognosis marker candidates of glioblastoma. As glioma is caused by EMT and maintained by glioma stem cells, in this study, we used the expression data and clinical information from 286 glioblastoma patients from TCGA and CGGA (Table S1) and focused on representative genes involved in EMT and glioma (Figure 1, Table S2) [34,35,36,37]. Expression of the 126 genes in 151 samples from the TCGA data set was shown with hierarchical clusters represented by heatmaps, including those in EPI (14 genes; Figure 1a), MES (23 genes; Figure 1b), GLI (53 genes; Figure 1c), GSCs (17 genes; Figure 1d), MTT (34 genes; Figure 1e), and PGBs (24 genes; Figure 1f).…”

Section: Resultsmentioning

confidence: 99%

Promising Prognosis Marker Candidates on the Status of Epithelial–Mesenchymal Transition and Glioma Stem Cells in Glioblastoma

Takashima

Kawaguchi

Yamanaka

2019

Cells

View full text Add to dashboard Cite

Multivariable analyses of global expression profiling are valid indicators of the prognosis of various diseases including brain cancers. To identify the candidates for markers of prognosis of glioblastoma, we performed multivariable analyses on the status of epithelial (EPI)-mesenchymal (MES) transition (EMT), glioma (GLI) stem cells (GSCs), molecular target therapy (MTT), and potential glioma biomarkers (PGBs) using the expression data and clinical information from patients. Random forest survival and Cox proportional hazards regression analyses indicated significant variable values for DSG3, CLDN1, CDH11, FN1, HDAC3/7, PTEN, L1CAM, OLIG2, TIMP4, IGFBP2, and GFAP. The analyses also comprised prognosis prediction formulae that could distinguish between the survival curves of the glioblastoma patients. In addition to the genes mentioned above, HDAC1, FLT1, EGFR, MGMT, PGF, STAT3, SIRT1, and GADD45A constituted complex genetic interaction networks. The calculated status scores obtained by principal component analysis indicated that GLI genes covered the status of EPI, GSC, and MTT-related genes. Moreover, survival tree analyses indicated that MES high , MES high GLI low , GSC high GLI low , MES high MTT low , and PGB high showed poor prognoses and MES middle , GSC low , and PGB low showed good prognoses, suggesting that enhanced EMT and GSC are associated with poor survival and that lower expression of EPI markers and the pre-stages of EMT are relatively less malignant in glioblastoma. These results demonstrate that the assessment of EMT and GSC enables the prediction of the prognosis of glioblastoma that would help develop novel therapeutics and de novo marker candidates for the prognoses of glioblastoma.

show abstract

Section: Resultsmentioning

confidence: 99%

Promising Prognosis Marker Candidates on the Status of Epithelial–Mesenchymal Transition and Glioma Stem Cells in Glioblastoma

Takashima

Kawaguchi

Yamanaka

2019

Cells

View full text Add to dashboard Cite

show abstract

“…Preliminary tests of the JNJ-42756493 drug in vitro and in vivo confirmed that growth of a tumor carrying recombinant FGFR-TACC was inhibited in two patients in whom the standard therapy had earlier been ineffective [101]. Some targeted drugs, such as MAb- 425 and nimotuzumab (targeted against EGFR), as well as crenolanib and nilotinib (targeted against PDGFR), are already in phases II–III of clinical trials [102]. At the same time, it is necessary to understand that the drugs that have shown good results in the treatment of intracranial astrocytomas may turn out to be ineffective against SCA, due to the possible differences in their genetic profiles.…”

Section: Introductionmentioning

confidence: 99%

Molecular Biomarkers of Brain and Spinal Cord Astrocytomas

et al. 2019

View full text Add to dashboard Cite

Spinal cord astrocytomas are rare diseases of the central nervous system. The localization of these tumors and their infiltrative growth complicate their surgical resection, increase the risk of postoperative complications, and require more careful use of radio- and chemotherapy. The information on the genetic mutations associated with the onset and development of astrocytomas provides a more accurate neoplasm diagnosis and classification. In some cases, it also allows one to determine the optimal methods for treating the neoplasm, as well as to predict the treatment outcomes and the risks of relapse. To date, a number of molecular markers that are associated with brain astrocytomas and possess prognostic value have been identified and described. Due to the significantly lower incidence of spinal cord astrocytomas, the data on similar markers are much more sparse and are presented with a lesser degree of systematization. However, due to the retrospective studies of clinical material that have been actively conducted abroad in recent years, the formation of statistically significant genetic landscapes for various types of tumors, including intradural spinal cord tumors, has begun. In this regard, the purpose of this review is to analyze and systematize the information on the most significant genetic mutations associated with various types of astrocytomas, as well as discuss the prospects for using the corresponding molecular markers for diagnostic and prognostic purposes.

show abstract

“…For example, heat shock proteins (HSPs), differentially expressed in AIH [13,14] are usually overexpressed in many human cancers and are implicated in tumor cell proliferation, differentiation, invasion and metastasis [13,14]. Especially, several HSPs, including HSP27 and HSP70 etc., are implicated with the prognosis of specific cancers.…”

Section: Introductionmentioning

confidence: 99%

Complementary serum proteomic analysis of autoimmune hepatitis in mice and patients

Zhao

et al. 2013

J Transl Med

Self Cite

View full text Add to dashboard Cite

BackgroundAutoimmune hepatitis (AIH) is a chronic liver disease caused by inflammation of the liver. The etiology of AIH remains elusive, and there are no reliable serum biomarkers.MethodsIn order to identify candidate biomarkers, 2-DE analysis of serum proteins was performed using a mouse model of AIH induced by treatment with concanavalin A (ConA). To enrich samples for low abundance molecules a commercial albumin removal reagent was used. In an independent analysis, candidate biomarkers were identified in AIH patient’s serum by a targeted iTRAQ (isobaric tags for relative and absolute quantification) identification. Candidates were validated in independent cohorts of ConA treated mice and AIH patients by ELISA (enzyme-linked immuno sorbent assay).ResultsNine proteins were differentially expressed in AIH mice treated with con-A. Two of these, the third component of complement (C3) and alpha-2-macroglobulin (A2M) were also up-regulated in AIH patient’s sera by a targeted iTRAQ identification. In separate validation studies, serum C3 and A2M levels were increased in mice with ConA treatment after 20-40 h and in 34 AIH patients in a subgroup analysis, females with AIH aged 20–50 years old displayed the largest increases in serum A2M level. Biological network analysis implements the complement cascade and protease inhibitors in the pathogenesis of AIH.ConclusionThe serum proteins C3 and A2M are increased both in a mouse model and in patients with AIH by both 2-DE and iTRAQ methods. This integrated serum proteomics investigation should be applicable for translational researchers to study other medical conditions.

show abstract

Biomarkers of Glioma

Cited by 8 publications

References 78 publications

Promising Prognosis Marker Candidates on the Status of Epithelial–Mesenchymal Transition and Glioma Stem Cells in Glioblastoma

Promising Prognosis Marker Candidates on the Status of Epithelial–Mesenchymal Transition and Glioma Stem Cells in Glioblastoma

Molecular Biomarkers of Brain and Spinal Cord Astrocytomas

Complementary serum proteomic analysis of autoimmune hepatitis in mice and patients

Contact Info

Product

Resources

About